As previously reported, H.C. Wainwright downgraded Kala Bio (KALA) to Neutral from Buy without a price target after KPI-012 failed to meet the primary or secondary endpoints in the Phase 2b CHASE trial for the treatment of persistent corneal epithelial defect. Management decided to cease development of KPI-012 and its mesenchymal stem cell secretome platform based on these results, which were “surprising” after the efficacy demonstrated in the Phase 1b trial was strong, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA: